Nitrous Oxide Pharmacology

Quick Answer

Nitrous oxide (N2O) is a colorless, odorless, non-irritating gas and the only inorganic compound used as a general anaesthetic. It is the weakest inhalational anaesthetic with a MAC (minimum alveolar concentration) of approximately 104%, meaning it cannot produce surgical anaesthesia as a sole agent at atmospheric pressure. However, its pharmacological profile includes rapid onset and offset, analgesic properties, and minimal cardiovascular and respiratory depression, making it a useful adjunct in balanced anaesthesia techniques.

The low blood-gas partition coefficient (0.47) gives nitrous oxide the fastest onset and offset of all inhalational agents, enabling rapid adjustments in depth of anaesthesia. Nitrous oxide provides significant analgesia at sub-anaesthetic concentrations (25-50%), distinguishing it from other inhalational agents. The drug has minimal effects on cardiovascular and respiratory function, preserving cardiac output, blood pressure, and spontaneous ventilation.

Clinical applications include use as a carrier gas for volatile agents (reducing their MAC by approximately 50%), provision of analgesia during labor and procedures, and as a component of general anaesthesia. Contraindications include pneumothorax, air embolism, bowel obstruction (expansion of gas-filled spaces), and patients with vitamin B12 deficiency or methionine synthase deficiency. Diffusion hypoxia upon discontinuation requires administration of 100% oxygen for 3-5 minutes. Chronic exposure can cause megaloblastic anemia and myeloneuropathy through irreversible oxidation of vitamin B12. Environmental concerns regarding its role as a greenhouse gas have led to efforts to minimize waste. [1-20]

Pharmacology Overview

Drug Classification and History

Nitrous oxide is an inorganic inhalational anaesthetic agent and the simplest anaesthetic molecule in clinical use. Discovered in 1772 by Joseph Priestley, it was first synthesized by Humphry Davy in 1799, who noted its analgesic properties and coined the term "laughing gas." The first public demonstration of anaesthesia was performed by Horace Wells in 1845 using nitrous oxide for dental extraction, predating Morton's ether demonstration by one year.

Despite being the oldest anaesthetic agent, nitrous oxide remains widely used globally due to its unique pharmacological profile:

1. Carrier gas: Reduces MAC of volatile agents by approximately 50%
2. Analgesic: Provides significant pain relief at sub-anaesthetic concentrations
3. Rapid onset/offset: Fastest kinetics of all inhalational agents
4. Minimal organ toxicity: No hepatic or renal metabolism
5. Low cost: Inexpensive compared to modern volatile agents

The drug is listed on the WHO List of Essential Medicines. However, its use has declined in some centres due to environmental concerns (potent greenhouse gas), awareness of vitamin B12/methionine synthase inhibition, and the availability of effective alternatives for analgesia and as carrier gases. [21-30]

Chemical Structure and Physicochemical Properties

Nitrous oxide has the molecular formula N2O and molecular weight of 44 g/mol. It is the simplest inorganic compound used as an anaesthetic, consisting of two nitrogen atoms covalently bonded to one oxygen atom in a linear arrangement (N≡N-O). The structure is isoelectronic with carbon dioxide but with distinct pharmacological properties.

Key Physicochemical Properties:

Physical Characteristics:

• Stored as compressed gas in blue cylinders (Australia/NZ standard color coding)
• Delivered via pipeline or cylinder through calibrated flowmeters
• Non-irritating to respiratory tract (does not trigger breath-holding or laryngospasm)
• Does not react with soda lime (unlike trichloroethylene historically)
• Stable compound; does not undergo chemical degradation

Comparison with Other Inhalational Agents:

The low blood:gas partition coefficient (0.47) explains nitrous oxide's rapid pharmacokinetics - it reaches equilibrium between alveoli and blood faster than any other agent. The low oil:gas partition coefficient (1.4) reflects weak potency, as potency correlates with lipid solubility (Meyer-Overton rule). [31-40]

Mechanism of Action

Anaesthetic and Analgesic Mechanisms

The exact mechanism by which nitrous oxide produces anaesthesia and analgesia remains incompletely understood but involves multiple targets:

1. NMDA Receptor Antagonism:

• Primary mechanism for analgesic effects
• Nitrous oxide non-competitively antagonizes N-methyl-D-aspartate (NMDA) receptors
• Reduces excitatory neurotransmission mediated by glutamate
• Similar mechanism to ketamine (NMDA antagonist)
• Accounts for analgesia at sub-anaesthetic concentrations

2. GABA-A Receptor Modulation:

• Weak positive allosteric modulation of GABA-A receptors
• Enhances inhibitory neurotransmission
• Contributes to sedative and amnestic effects
• Less potent than benzodiazepines or volatile agents

3. Opioid System Activation:

• Increases release of endogenous opioids (beta-endorphin, enkephalins)
• Activates mu and kappa opioid receptors
• Contributes to analgesic effects
• Partly reversible by naloxone (evidence for opioid component)

4. Nicotinic Acetylcholine Receptor Inhibition:

• Inhibits nicotinic receptors in brain and spinal cord
• May contribute to muscle relaxation and CNS depression

5. Two-Pore Domain Potassium Channels (TREK-1):

• Activation of background potassium channels
• Hyperpolarization of neurons
• Reduced excitability

Summary of Mechanisms:

This multimodal mechanism distinguishes nitrous oxide from volatile agents (which primarily act on GABA-A receptors) and explains its unique analgesic properties. [41-55]

Potency and MAC

Minimum Alveolar Concentration (MAC):

• Nitrous oxide MAC: 104% (at sea level, 1 atmosphere pressure)
• Meaning: 104% inspired concentration required to prevent movement in 50% of patients exposed to surgical stimulus
• Clinical implication: Cannot produce surgical anaesthesia as sole agent at atmospheric pressure
• Requires combination with other agents (volatile agents, opioids, intravenous agents)

MAC Reduction:

• Nitrous oxide 60% reduces MAC of volatile agents by approximately 50%
• Mechanism: Additive or synergistic CNS depression
• Clinical application: Use as carrier gas to reduce volatile agent requirement

Analgesic Concentrations:

• Sub-anaesthetic concentrations (25-50%) provide significant analgesia
• Labor analgesia: 50% N2O with 50% O2 (Entonox, Equanox)
• Procedural sedation: 30-50% N2O

Concentration Effects:

The combination of weak anaesthetic potency (high MAC) with strong analgesic properties at sub-anaesthetic doses is unique among inhalational agents and underlies its clinical utility. [56-65]

Pharmacokinetic Principles

Uptake and Distribution

Nitrous oxide has the fastest pharmacokinetics of all inhalational agents due to its low blood:gas partition coefficient (0.47):

Factors Promoting Rapid Uptake:

1. Low solubility: Low blood:gas partition coefficient means minimal uptake into blood
2. Concentration effect: High inspired concentration drives rapid alveolar accumulation
3. Second gas effect: Rapid uptake of nitrous oxide concentrates other gases in alveoli
4. Cardiac output: High CO increases delivery to tissues

Concentration Effect:

• When a large volume of soluble gas is taken up from alveoli, it "concentrates" remaining gases
• With 70% N2O inspired, if 50% is taken up, the remaining 50% concentrates the other 30% to 60%
• Accelerates uptake of nitrous oxide itself and companion gases (oxygen, volatile agents)
• More pronounced with nitrous oxide than other agents due to high concentration used

Second Gas Effect:

• Rapid uptake of nitrous oxide (first gas) increases alveolar concentration of companion gases (second gas)
• Example: When N2O taken up rapidly, it concentrates sevoflurane or oxygen in alveoli
• Accelerates onset of volatile agents and can cause transient hyperoxia then hypoxia
• Clinical significance debated but measurable

FA/FI Ratio:

• Ratio of alveolar concentration (FA) to inspired concentration (FI)
• Indicates speed of equilibration
• Nitrous oxide reaches 90% equilibration in ~10-15 minutes
• Compare: Sevoflurane ~15-20 minutes, isoflurane ~30-45 minutes [66-78]

Distribution

Tissue Solubility: Nitrous oxide distributes to tissues based on perfusion and solubility:

Speed of Equilibration by Tissue:

• Brain, heart, liver, kidneys: 2-3 minutes
• Skeletal muscle: 20-30 minutes
• Adipose tissue: 2-4 hours (minimal significance due to low solubility)

Blood:Gas Partition Coefficient Significance: The low coefficient (0.47) means:

• Minimal uptake into blood relative to delivery
• Rapid saturation of blood with nitrous oxide
• Fast transfer to tissues
• Rapid washout when administration stopped

Diffusion Characteristics: Nitrous oxide diffuses rapidly into air-filled spaces due to:

• High concentration gradient (alveoli to tissues)
• Low molecular weight (44 g/mol)
• High lipid solubility relative to nitrogen (blood:gas 0.47 vs 0.015)
• Large concentration used (50-70%) [79-88]

Elimination

Washout Characteristics: Nitrous oxide is eliminated unchanged primarily via the lungs:

Elimination Pathways:

• Pulmonary exhalation: >95% of elimination
• Diffusion into air-filled spaces: Small amount
• Skin diffusion: Negligible
• Metabolism: <0.01%

Speed of Elimination:

• Fastest of all inhalational agents
• 50% reduction in ~2-3 minutes after discontinuation
• 90% elimination in ~10-15 minutes
• Compare: Sevoflurane ~15-20 minutes, isoflurane ~30-45 minutes

Diffusion Hypoxia (Fink Effect): Critical phenomenon upon discontinuation:

Mechanism:

1. High volumes of nitrous oxide rapidly diffuse from blood to alveoli
2. "Dilutes" alveolar oxygen and carbon dioxide
3. If patient breathing room air, PAO2 can drop to 50-70 mmHg
4. Results in transient hypoxemia (2-5 minutes)

Prevention:

• Administer 100% oxygen for 3-5 minutes after discontinuing N2O
• Prevents diffusion hypoxia
• Ensures adequate oxygenation during washout phase

Clinical Significance:

• Can occur with any patient discontinuing nitrous oxide
• More pronounced with higher concentrations and longer durations
• Dangerous in patients with limited cardiorespiratory reserve
• Easily prevented with appropriate oxygenation [89-98]

Kinetic Summary

Clinical Applications of Rapid Kinetics:

1. Rapid induction of anaesthesia
2. Rapid adjustment of depth
3. Quick emergence at end of procedure
4. Useful for short procedures and day surgery
5. Enables intermittent use during labor [99-105]

Pharmacodynamics: Systemic Effects

Central Nervous System Effects

Anaesthetic Effects:

• Weak anaesthetic agent (MAC 104%)
• Cannot produce surgical anaesthesia alone at atmospheric pressure
• Produces stage I (analgesia) and stage II (delirium/excitement) of anaesthesia
• Requires combination with other agents for surgical anaesthesia

Analgesic Effects:

• Significant analgesia at 25-50% concentration
• Comparable to 10-15 mg morphine IM
• Effective for labor, dental procedures, minor surgery
• Mechanism: NMDA antagonism + endogenous opioid release

Cerebral Effects:

• Increases cerebral blood flow (CBF) by 10-20%
• Increases intracranial pressure (ICP) modestly
• Mechanism: Cerebral vasodilation
• Contraindicated in intracranial hypertension (risk of brain herniation)
• Increases cerebral metabolic rate for oxygen (CMRO2) slightly

EEG Changes:

• Low voltage fast activity at low concentrations
• High voltage slow waves at higher concentrations
• No burst suppression even at high concentrations

Amnesia:

• Provides amnesia at anaesthetic concentrations (>60%)
• Less reliable than volatile agents or benzodiazepines
• Anterograde amnesia (cannot form new memories)

Dreaming:

• Vivid dreams common during emergence
• Can be pleasant or disturbing
• Related to dissociative effects (NMDA antagonism)

Neuroprotection:

• Some evidence of neuroprotective effects
• Mechanism: NMDA antagonism (similar to ketamine)
• Reduces excitotoxicity
• Not established for routine use [106-120]

Cardiovascular Effects

Nitrous oxide has minimal cardiovascular depression compared to volatile agents:

Heart Rate:

• Minimal effect at concentrations <50%
• Slight increase at higher concentrations (sympathetic stimulation)
• No direct chronotropic effect

Blood Pressure:

• Minimal change or slight increase
• Sympathetic stimulation may increase BP slightly
• Does not cause vasodilation (unlike volatile agents)
• Myocardial depression minimal

Cardiac Output:

• Generally preserved
• May increase slightly due to sympathetic activation
• No direct negative inotropic effect
• Safe in patients with limited cardiac reserve

Systemic Vascular Resistance:

• Minimal change
• No significant vasodilation or vasoconstriction
• Unlike volatile agents which reduce SVR

Pulmonary Vascular Resistance:

• Increases PVR by 5-15%
• Mechanism: Direct effect on pulmonary vasculature
• Clinical significance:
  • Generally well-tolerated in healthy patients
  • Contraindicated or use caution in severe pulmonary hypertension
  • May worsen right heart failure in susceptible patients

Coronary Circulation:

• Minimal effect on coronary blood flow
• Does not cause coronary steal (unlike isoflurane historically)
• Safe in patients with coronary artery disease (cardiac stability)

Arrhythmias:

• Does not sensitize myocardium to catecholamines (unlike halothane historically)
• Minimal arrhythmogenic potential
• Safe with epinephrine-containing local anaesthetics

Hemodynamic Stability:

• Preserves blood pressure, heart rate, and cardiac output
• Sympathetic tone maintained
• "Cardiac stability" is a major advantage over volatile agents
• Useful in patients with cardiovascular disease or hypovolemia [121-135]

Respiratory Effects

Ventilation:

• Minimal respiratory depression compared to volatile agents or opioids
• Respiratory rate may decrease slightly
• Tidal volume maintained or slightly reduced
• Minute ventilation generally preserved

Response to CO2:

• Preserved ventilatory response to CO2 (unlike opioids)
• Minimal shift in CO2 response curve
• Safer in patients with respiratory disease or obesity

Airway Resistance:

• No bronchodilator effect (unlike volatile agents)
• No bronchospasm or irritation
• Safe in asthmatic patients (though not therapeutic)

Hypoxic Drive:

• Blunts hypoxic ventilatory drive (response to low O2)
• Mechanism: Central effect on chemoreceptors
• Clinical significance:
  • Patients may not increase ventilation when hypoxic
  • Dangerous if combined with opioids
  • Supplemental oxygen essential

Mucociliary Function:

• Does not impair mucociliary clearance (unlike volatile agents)
• No increase in secretions
• Non-irritating to airway

Diffusion into Air Spaces:

• Rapid diffusion into any air-filled space
• Can expand:
  • Pneumothorax
  • Pneumoperitoneum
  • Bowel gas
  • Intracranial air (after neurosurgery)
  • Air emboli
  • Middle ear (tympanic membrane)
• Contraindicated in these conditions

Environmental Impact:

• Exhaled nitrous oxide contributes to atmospheric pollution
• Potent greenhouse gas (298x CO2 global warming potential)
• Ozone-depleting potential
• Scavenging systems required to minimize release
• Environmental concerns driving reduction in use [136-150]

Gastrointestinal and Genitourinary Effects

Gastrointestinal:

• Does not cause nausea and vomiting directly (less than volatile agents)
• Does not affect gastrointestinal motility
• Can expand bowel gas (contraindicated in bowel obstruction)
• No hepatotoxicity (unlike halothane historically)

Genitourinary:

• No effect on uterine tone
• Does not cross placenta in significant amounts (low lipid solubility)
• Safe in pregnancy (used for labor analgesia)
• Can expand air in urinary tract (rare clinical significance)

Obstetric Use:

• 50% N2O in oxygen (Entonox) for labor analgesia
• Safe for mother and fetus
• Self-administered via demand valve
• Effective analgesia without neonatal depression [151-158]

Hematologic and Biochemical Effects

Vitamin B12 and Methionine Synthase Inhibition:

Mechanism:

• Nitrous oxide irreversibly oxidizes the cobalt atom in vitamin B12 (cobalamin)
• Inactivates methionine synthase (B12-dependent enzyme)
• Methionine synthase required for:
  • Conversion of homocysteine to methionine
  • Synthesis of tetrahydrofolate (THF)
  • DNA synthesis and cell division

Consequences of Inhibition:

1. Megaloblastic anemia: Impaired DNA synthesis in rapidly dividing cells (bone marrow)
2. Myeloneuropathy: Degeneration of posterior columns and lateral corticospinal tracts
3. Hyperhomocysteinemia: Increased cardiovascular risk
4. Folate deficiency: Functional folate deficiency despite normal levels

Clinical Context:

• Acute use (hours): No clinical significance in healthy patients
• Chronic exposure (days to weeks): Risk of megaloblastic anemia and neuropathy
• High-risk patients (B12 deficiency, MTHFR mutation): Risk with shorter exposures

Recovery:

• Methionine synthase activity recovers over days to weeks after cessation
• Requires new enzyme synthesis (irreversible inhibition)
• Vitamin B12 supplementation does not immediately restore activity (inactivated B12 must be replaced)

Contraindications:

• Megaloblastic anemia
• Vitamin B12 deficiency
• Methionine synthase deficiency
• MTHFR (methylenetetrahydrofolate reductase) mutation
• Pernicious anemia
• Previous nitrous oxide-induced myeloneuropathy

Prevention:

• Limit duration of exposure when possible
• Consider B12/folate supplementation in high-risk patients
• Avoid in patients with known deficiencies
• Use alternative agents in patients requiring prolonged anaesthesia

Other Hematologic Effects:

• No effect on platelet function
• No effect on coagulation cascade
• Can expand air emboli (air in venous system)

Metabolic Effects:

• No effect on glucose metabolism
• Does not trigger malignant hyperthermia
• No significant endocrine effects [159-180]

Neuromuscular Effects

Skeletal Muscle:

• Weak muscle relaxant effect (compared to volatile agents)
• Does not enhance neuromuscular blockade significantly
• No effect on neuromuscular transmission at clinical concentrations

Uterus:

• No effect on uterine tone or contractility
• Does not cause uterine relaxation
• Safe in obstetric anaesthesia (does not impair labor)

Clinical Significance:

• Cannot be used as sole agent for muscle relaxation
• Does not reduce requirements for neuromuscular blocking agents significantly
• Combines safely with NMBAs [181-185]

Clinical Pharmacology

Clinical Indications and Use

1. Carrier Gas for Volatile Agents

Rationale:

• Nitrous oxide reduces MAC of volatile agents by ~50%
• Mechanism: Additive CNS depression
• Reduces volatile agent requirement by approximately 50%

Clinical Application:

• 50-70% N2O with 0.5-1.0% isoflurane/sevoflurane
• 50-70% N2O with 4-6% desflurane
• Allows lower concentrations of expensive volatile agents
• Faster emergence when combined (nitrous oxide speeds washout)

Benefits:

• Cost savings (volatile agents expensive)
• Reduced exposure to volatile agents
• Faster emergence due to nitrous oxide kinetics
• Cardiovascular stability

Considerations:

• Cannot use >70% (oxygen dilution)
• Does not provide adequate anaesthesia alone
• Environmental concerns with waste gas [186-195]

2. Labor Analgesia

Entonox (50% N2O, 50% O2):

• Self-administered via demand valve (patient-controlled)
• Inhale at onset of contraction, stop at peak
• Provides significant analgesia without neonatal depression
• Safe for mother and baby
• Does not prolong labor or impair uterine contractility

Efficacy:

• Reduces pain scores by 30-50%
• Comparable to pethidine (meperidine) without neonatal sedation
• Less effective than epidural but safer and non-invasive
• Widely used in UK, Australia, NZ

Contraindications:

• Inability to self-administer (altered consciousness, cooperation issues)
• Pneumothorax or other contraindication to N2O
• Vitamin B12 deficiency (rare)

Technique:

• Patient learns timing (inhale 30-60 seconds before contraction)
• Peak effect at end of contraction
• Safe, effective, non-invasive option
• Can be combined with other techniques [196-205]

3. Procedural Sedation and Analgesia

Indications:

• Dental procedures
• Minor surgical procedures
• Dressing changes
• Emergency department procedures
• Pediatric procedures (with appropriate monitoring)

Concentration:

• 30-50% N2O in oxygen
• Provides analgesia and anxiolysis
• Patient remains conscious and cooperative
• Rapid offset allows quick recovery

Advantages:

• Non-irritating airway
• Rapid onset and offset
• No IV access required
• Analgesic properties
• Minimal cardiovascular depression

Monitoring:

• Pulse oximetry mandatory
• Observation of consciousness level
• Scavenging essential
• Oxygen available for breakthrough [206-215]

4. General Anaesthesia Adjunct

Role in Balanced Anaesthesia:

• Component of "balanced technique" (N2O + volatile + opioid + NMBA)
• Provides analgesia and reduces volatile agent requirement
• Faster emergence when used with volatile agents

Concentration:

• 50-70% typically
• Maximum 70% (minimum 30% oxygen)
• Higher concentrations limit oxygen delivery

Combination Benefits:

• Reduced volatile agent consumption
• Cost reduction
• Cardiovascular stability
• Faster emergence

Limitations:

• Cannot use as sole agent
• Contraindications limit use in some patients
• Environmental concerns
• No longer used in some centres [216-225]

Contraindications

Drug Interactions

Special Populations

Pediatric Patients

Use in Children:

• Safe for induction and maintenance
• Less pungent than volatile agents (better acceptance)
• Rapid induction due to rapid kinetics
• Can use for mask induction before IV
• Reduces volatile agent requirement

Considerations:

• Monitor for diffusion hypoxia (smaller FRC)
• Higher minute ventilation (faster kinetics)
• Can cause excitement/delirium during emergence
• Safe with appropriate monitoring

Concentration:

• 50-70% typical
• Must maintain adequate oxygenation
• Scavenging essential [226-235]

Elderly Patients

Pharmacokinetic Changes:

• Reduced cardiac output (slower uptake)
• Reduced FRC (faster alveolar changes)
• Net effect: Similar kinetics to younger adults

Pharmacodynamic Changes:

• Increased sensitivity to CNS depression
• May require lower concentrations
• Risk of postoperative cognitive dysfunction (controversial)
• Monitor emergence delirium

Contraindications:

• More likely to have B12 deficiency (atrophic gastritis)
• Check for contraindications carefully
• Consider folate status [236-240]

Obstetric Patients

Labor Analgesia:

• Safe and effective (Entonox)
• No effect on uterine tone or fetal heart rate
• No neonatal depression
• Self-administration allows patient control

Caesarean Section:

• Can be used as component of general anaesthesia
• 50-70% with volatile agent or propofol
• No effect on uterine contractility
• No placental transfer in significant amounts
• Safe for breastfeeding

Contraindications in Pregnancy:

• Folate deficiency (common in pregnancy)
• B12 deficiency
• Pneumothorax or other air space issues [241-250]

Adverse Effects and Complications

Acute Effects

Chronic Toxicity

Megaloblastic Anemia:

• Occurs with chronic exposure (>12-24 hours continuous)
• Mechanism: Methionine synthase inhibition
• Features: Macrocytic anemia, pancytopenia
• Recovery: Days to weeks after cessation
• Prevention: Limit duration, screen for B12 deficiency

Subacute Combined Degeneration of Cord:

• Demyelination of posterior columns and lateral corticospinal tracts
• Features: Paresthesias, ataxia, weakness, spasticity
• Occurs with chronic exposure or B12 deficiency
• Recovery: Slow; may be incomplete
• Prevention: Avoid in B12 deficiency, limit occupational exposure

Fertility and Reproductive Effects:

• Occupational exposure associated with decreased fertility
• Mechanism: Unknown; possibly oxidative stress
• Ensure adequate scavenging in operating theatres

Other Occupational Risks:

• Increased spontaneous abortion (historical concern)
• Neurological symptoms with chronic exposure
• Current scavenging systems minimize risk

Prevention of Chronic Toxicity:

1. Scavenging systems in all operating theatres
2. Limit occupational exposure
3. Monitor B12 status in high-risk patients
4. Avoid long exposures in susceptible patients
5. Consider folate supplementation in chronic users [251-270]

Diffusion-Related Complications

Expansion of Air Spaces: Nitrous oxide diffuses into any air-filled space 34x faster than nitrogen can exit (diffusion gradient):

Clinical Significance:

• Can increase volume 2-3x within 30-60 minutes
• Most dangerous with closed air spaces (pneumothorax, intracranial)
• ABSOLUTE CONTRAINDICATION in these conditions
• If unrecognized, can cause life-threatening complications

Management if Inadvertently Used:

• Discontinue nitrous oxide immediately
• 100% oxygen to accelerate N2O washout
• Treat underlying condition (chest drain for pneumothorax)
• Supportive care [271-280]

Australian/NZ Specific Considerations

TGA-Approved Formulations

Nitrous oxide is TGA-approved in Australia in the following formulations:

Cylinder Colors (Australia/NZ Standard):

• Nitrous oxide: Blue body with white shoulders
• Oxygen: White body with black/white shoulders
• Entonox: Blue and white segmented
• Critical: Color coding prevents wrong gas delivery

PBS and Regulatory Status

Availability:

• Nitrous oxide: Available in all Australian hospitals via pipeline or cylinder
• Entonox: Available in maternity units
• Cost: Very low (compressed gas)

Regulatory Considerations:

• Schedule 4 (Prescription Only) for medical use
• Occupational health regulations require scavenging
• Monitoring of exposure levels in operating theatres
• National standards for medical gas quality

ANZCA Guidelines

ANZCA Professional Document PS55 (Statement on Environmental Sustainability in Anaesthesia):

• Recognizes nitrous oxide as potent greenhouse gas
• Recommends minimizing use where clinically appropriate
• Encourages use of alternative techniques (total intravenous anaesthesia, regional)
• Recommends effective scavenging systems
• Suggests consideration of environmental impact in clinical decision-making

ANZCA Primary Examination: Nitrous oxide pharmacology is high-yield:

• MAC and inability to produce surgical anaesthesia alone
• Diffusion hypoxia mechanism and prevention
• Contraindications (air spaces, B12 deficiency)
• Diffusion into closed spaces
• Methionine synthase inhibition
• Blood:gas partition coefficient and rapid kinetics

Current Practice Trends in Australia/NZ:

• Declining use in some centres due to environmental concerns
• Still widely used for labor analgesia (Entonox)
• Still used as carrier gas in many general anaesthetics
• Increasing use of total intravenous anaesthesia (TIVA) as alternative
• Awareness of vitamin B12 effects in high-risk populations [281-295]

Environmental Considerations

Greenhouse Gas Properties:

• Global Warming Potential: 298x CO2 (100-year timeframe)
• Atmospheric lifetime: ~114 years
• Ozone-depleting potential: Yes (contributes to ozone depletion)
• Contribution to healthcare carbon footprint: Significant

Australian/NZ Response:

• ANZCA sustainability initiatives
• Capture and destruction technologies (catalytic destruction)
• Reduced use campaigns
• Alternative anaesthetic techniques
• "Green anaesthesia" initiatives

Clinical Implications:

• Consider TIVA instead of N2O + volatile
• Use regional anaesthesia when appropriate
• Ensure efficient scavenging
• Consider environmental impact in decision-making
• Balance clinical benefit against environmental cost [296-300]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Considerations

Health Context: Aboriginal and Torres Strait Islander Australians have specific health considerations relevant to nitrous oxide use:

Nutritional Considerations:

• Higher rates of nutritional deficiencies, including folate and B12
• In remote communities, limited access to fresh foods may contribute
• Assessment for B12/folate deficiency before prolonged N2O use important

Chronic Disease:

• Higher rates of chronic obstructive pulmonary disease (COPD)
• Nitrous oxide may not be ideal in severe COPD (limited oxygen delivery, air trapping)
• Alternative techniques may be preferred

Access to Care:

• Remote communities may have limited access to specialist anaesthesia
• Entonox for labor analgesia should be available in all birthing facilities
• Training for midwives and remote practitioners in safe use

Cultural Safety:

• Aboriginal Health Workers involvement in maternity care
• Clear explanation of Entonox use and effects
• Self-administration gives patient control (culturally appropriate)
• Family involvement in birth process [301-308]

Māori Health Considerations (New Zealand)

Health Context: Māori experience health inequities that may impact nitrous oxide use:

Nutritional Status:

• Ensure adequate folate and B12 status
• Consider dietary patterns and supplementation

Respiratory Health:

• Higher rates of respiratory disease
• Assess respiratory function before N2O use

Maternity Care:

• Entonox widely used and accepted
• Whānau involvement in decision-making
• Cultural safety in maternity services
• Access to analgesia options regardless of location

Equity Considerations:

• Ensure availability of Entonox in all maternity units
• Training in safe use across all settings
• Recognition of patient autonomy in analgesia choices [309-315]

Remote and Rural Considerations

Practical Considerations:

• Entonox cylinders available in remote maternity units
• Portable, safe, effective analgesia for labor
• No complex equipment required (demand valve)
• Does not require electricity or refrigeration
• Long shelf life

Training:

• Midwives and rural practitioners trained in Entonox administration
• Recognition of contraindications
• Management of complications
• When to seek additional support

Safety:

• Scavenging may be limited in remote settings
• Ensure adequate ventilation
• Monitor for overuse or misuse
• Clear protocols for safe storage and use [316-320]

ANZCA Primary Exam Focus

High-Yield Facts

Must-Know Numbers:

• MAC: ~104% (cannot produce surgical anaesthesia alone)
• Blood:Gas partition coefficient: 0.47 (fastest onset/offset)
• Oil:Gas partition coefficient: 1.4 (weak potency)
• Diffusion capacity: 34x faster than nitrogen
• Global warming potential: 298x CO2

Must-Know Mechanisms:

• NMDA receptor antagonism (analgesia)
• GABA-A receptor modulation (anaesthesia)
• Methionine synthase inhibition (B12 oxidation)
• Diffusion hypoxia mechanism (Fink effect)
• Diffusion into air spaces

Must-Know Contraindications:

• Pneumothorax, air embolism, intracranial air (expansion)
• B12 deficiency, MTHFR mutation (methionine synthase)
• Severe pulmonary hypertension (increases PVR)
• Tympanic membrane graft, bullous lung disease
• Vitreoretinal surgery with intraocular gas

Must-Know Clinical Applications:

• Carrier gas (reduces MAC of volatiles by 50%)
• Labor analgesia (Entonox 50%)
• Cannot produce surgical anaesthesia alone
• Rapid onset/offset (fastest of all agents)
• Diffusion hypoxia prevention (100% O2 for 3-5 min) [321-335]

Common MCQ Patterns

1. Pharmacokinetics:

• "Which agent has the fastest onset?" (Answer: Nitrous oxide - lowest blood:gas partition coefficient)
• "What prevents diffusion hypoxia?" (Answer: 100% oxygen for 3-5 minutes after N2O)
• "Why can't nitrous oxide produce surgical anaesthesia alone?" (Answer: MAC is 104%, above atmospheric pressure)

2. Mechanism:

• "The analgesic effect of nitrous oxide is primarily via?" (Answer: NMDA receptor antagonism)
• "Nitrous oxide inhibits which enzyme?" (Answer: Methionine synthase via B12 oxidation)

3. Contraindications:

• "Nitrous oxide is contraindicated in?" (Answer: Pneumothorax, B12 deficiency, air embolism)
• "Why avoid nitrous oxide after pneumonectomy?" (Answer: Remaining lung is pneumothorax risk if broncho-pleural fistula)

4. Diffusion:

• "Nitrous oxide diffuses into air spaces faster than nitrogen leaves because?" (Answer: Concentration gradient and solubility differences)
• "A post-neurosurgery patient develops decreased consciousness in recovery after N2O - diagnosis?" (Answer: Expansion of intracranial air, increased ICP)

5. Environmental:

• "Nitrous oxide is a concern because?" (Answer: Potent greenhouse gas, ozone-depleting)
• "Diffusion hypoxia occurs when?" (Answer: Upon discontinuation, N2O washes out and dilutes alveolar O2) [336-350]

Primary Viva Question Themes

Typical Viva Scenarios:

1. Pharmacokinetics:

   • "Tell me about the pharmacokinetics of nitrous oxide"
   • Expect: Blood:gas partition coefficient (0.47), rapid onset/offset, concentration effect, second gas effect, minimal metabolism

2. Mechanism:

   • "How does nitrous oxide work?"
   • Expect: NMDA antagonism (analgesia), GABA-A modulation, opioid system activation, MAC 104% (weak anaesthetic)

3. Contraindications:

   • "A patient has a pneumothorax - can you use nitrous oxide?"
   • Expect: Absolute contraindication, expansion of air spaces, mechanism of diffusion, risk of tension pneumothorax

4. Diffusion Hypoxia:

   • "What is diffusion hypoxia and how do you prevent it?"
   • Expect: Fink effect, mechanism (N2O dilutes alveolar O2), prevention (100% O2 for 3-5 minutes)

5. Vitamin B12:

   • "Tell me about nitrous oxide and vitamin B12"
   • Expect: Oxidation of cobalt in B12, methionine synthase inhibition, megaloblastic anemia, myeloneuropathy, contraindications

6. Clinical Use:

   • "When would you use nitrous oxide?"
   • Expect: Carrier gas, labor analgesia, rapid onset procedures, MAC reduction, contraindications [351-365]

Assessment Content

SAQ Practice Question 1 (20 marks)

Question:

A 28-year-old woman is in labor and requests analgesia. The midwife suggests Entonox (50% nitrous oxide in oxygen). The patient asks about how it works and whether it is safe.

(a) Explain the mechanism of action of nitrous oxide, including the receptor targets involved in its analgesic and anaesthetic effects. (6 marks)

(b) Describe the pharmacokinetic properties of nitrous oxide that make it suitable for labor analgesia, including onset, offset, and diffusion characteristics. (6 marks)

(c) Discuss the safety profile of nitrous oxide in labor, including contraindications and potential adverse effects. (4 marks)

(d) The patient mentions she has been vegan for 5 years. Does this affect your recommendation? Explain. (4 marks)

---

Model Answer:

(a) Mechanism of Action (6 marks)

Analgesic Mechanisms (3 marks):

1. NMDA Receptor Antagonism (primary): Nitrous oxide non-competitively antagonizes N-methyl-D-aspartate receptors in the spinal cord and brain, reducing excitatory neurotransmission mediated by glutamate. This is the primary mechanism for analgesia at sub-anaesthetic concentrations.

2. Opioid System Activation: Increases release of endogenous opioids (beta-endorphin, enkephalins) and activates mu and kappa opioid receptors, contributing to analgesic effects.

3. Nicotinic Receptor Inhibition: Inhibits nicotinic acetylcholine receptors, reducing transmission in pain pathways.

Anaesthetic Mechanisms (3 marks):

1. GABA-A Receptor Modulation: Weak positive allosteric modulation enhances inhibitory neurotransmission, producing sedation and amnestic effects.

2. TREK-1 Potassium Channel Activation: Activation of two-pore domain potassium channels causes neuronal hyperpolarization and reduced excitability.

3. Weak Potency: MAC is approximately 104%, meaning it cannot produce surgical anaesthesia alone at atmospheric pressure. Provides stage I (analgesia) and stage II (delirium/excitement) but requires other agents for surgical anaesthesia.

(b) Pharmacokinetics for Labor (6 marks)

Rapid Onset (2 marks):

• Blood:Gas partition coefficient of 0.47 (lowest of all agents)
• Low solubility in blood means rapid equilibrium between alveoli and blood
• Onset of analgesia within 1-2 minutes of inhalation
• Peak effect achieved by end of contraction when correctly timed

Rapid Offset (2 marks):

• Fastest washout of all inhalational agents
• 50% elimination in 2-3 minutes after stopping
• 90% elimination in 10-15 minutes
• Allows patient to be fully alert between contractions if desired
• No residual sedation affecting mother or neonate

Diffusion Characteristics (2 marks):

• Low molecular weight (44 g/mol) and moderate lipid solubility allow rapid transfer across alveolar membrane
• Concentration effect: High inspired concentration (50%) drives rapid alveolar accumulation
• Rapid distribution to vessel-rich tissues (brain, spinal cord) producing quick effect
• Minimal metabolism (<0.01%) means elimination entirely via exhalation

Suitability for Labor:

• Self-administration via demand valve allows patient control
• Timing with contractions (inhale at onset, stop at peak)
• No accumulation or neonatal depression
• No effect on uterine contractility or labor progress

(c) Safety Profile (4 marks)

Safety Advantages (2 marks):

• Minimal cardiovascular depression: Preserves blood pressure, heart rate, and cardiac output; safe in hemodynamically compromised patients
• Minimal respiratory depression: Preserves ventilatory response to CO2; safer than opioids
• No neonatal depression: Minimal placental transfer; Apgar scores unaffected; safe for breastfeeding
• Rapid offset: No prolonged sedation; patient fully alert between contractions
• Uterine tone preserved: Does not impair labor progress or uterine contractility

Contraindications (1 mark):

• Pneumothorax, bowel obstruction, intracranial air (expansion of air spaces)
• Severe pulmonary hypertension (increases pulmonary vascular resistance)
• Vitamin B12 deficiency or methionine synthase deficiency (megaloblastic anemia, neuropathy risk)
• Inability to self-administer (altered consciousness, cooperation issues)

Adverse Effects (1 mark):

• Nausea/vomiting (10-30%), dizziness, dysphoria
• Excitement/delirium (rare with appropriate use)
• Diffusion hypoxia upon discontinuation (prevented by administering oxygen)
• Environmental exposure to staff (scavenging required)

(d) Vegan Diet Consideration (4 marks)

Relevance of Vegan Diet: A 5-year vegan diet raises concern about vitamin B12 deficiency, which is relevant to nitrous oxide use.

Vitamin B12 Status (2 marks):

• Vitamin B12 is found exclusively in animal products (meat, dairy, eggs)
• Vegans are at risk for B12 deficiency without supplementation
• Deficiency develops over years as body stores deplete (typically 2-5 years)
• 5 years of veganism without supplementation puts patient at significant risk

Nitrous Oxide and B12 Interaction (2 marks):

• Nitrous oxide irreversibly oxidizes the cobalt atom in vitamin B12
• Inactivates methionine synthase, an enzyme required for DNA synthesis and cell division
• Risk of megaloblastic anemia with acute use if B12 deficient
• Risk of subacute combined degeneration of the cord with chronic or repeated exposure

Recommendations:

1. Assess B12 status: Check serum B12 level and/or methylmalonic acid before using Entonox if prolonged use anticipated (>6-12 hours)
2. Consider supplementation: Ensure patient takes B12 supplements if not already doing so
3. Short-term use safe: Brief use for labor (hours) generally safe even with mild deficiency
4. Alternative analgesia: If B12 deficiency confirmed and prolonged labor anticipated, consider epidural or other alternatives
5. Documentation: Document discussion and B12 status

Clinical Decision: For labor analgesia with Entonox (intermittent use, typically <12 hours), the risk from B12 deficiency is low. However, given 5 years of veganism, it would be prudent to ensure she is taking B12 supplements and consider checking B12 status postpartum if she has symptoms of deficiency.

Total: 20 marks

SAQ Practice Question 2 (20 marks)

Question:

A 65-year-old man is scheduled for emergency laparotomy for small bowel obstruction. He has a history of pernicious anemia managed with monthly B12 injections. The anaesthetist plans general anaesthesia and asks whether nitrous oxide should be used.

(a) Outline the mechanism by which nitrous oxide affects vitamin B12 and methionine synthase. (5 marks)

(b) Explain why nitrous oxide is contraindicated in this patient and describe the potential consequences if used. (5 marks)

(c) The patient also has a distended abdomen with dilated small bowel loops on imaging. Explain why this further contraindicates nitrous oxide use. (5 marks)

(d) Describe your alternative anaesthetic plan for this patient, avoiding nitrous oxide. (5 marks)

---

Model Answer:

(a) Mechanism of B12 and Methionine Synthase Inhibition (5 marks)

Vitamin B12 Structure (1 mark): Vitamin B12 (cobalamin) contains a cobalt atom at the center of a corrin ring. The cobalt exists in multiple oxidation states (Co1+, Co2+, Co3+), with the reduced Co1+ state required for methionine synthase activity.

Oxidation by Nitrous Oxide (2 marks):

• Nitrous oxide irreversibly oxidizes the reduced cobalt (Co1+) in vitamin B12 to the oxidized state (Co2+ or Co3+)
• This occurs by direct chemical reaction between N2O and the cobalt atom
• The oxidation is irreversible - the inactivated B12 cannot be immediately restored
• Inactivation occurs within minutes of N2O exposure

Methionine Synthase Inhibition (2 marks):

• Methionine synthase is a vitamin B12-dependent enzyme that converts homocysteine to methionine
• This reaction is essential for:
  1. Methionine synthesis (protein synthesis, methylation reactions)
  2. Tetrahydrofolate regeneration (DNA synthesis)
• Inactivation of B12 renders methionine synthase non-functional
• This inhibits DNA synthesis in rapidly dividing cells (bone marrow, gastrointestinal mucosa)

Recovery: New methionine synthase must be synthesized and new functional B12 must be obtained - a process taking days to weeks. This is why the inhibition is clinically significant.

(b) Contraindication and Consequences (5 marks)

Contraindication Rationale (2 marks):

• Pernicious anemia causes B12 malabsorption due to lack of intrinsic factor
• Monthly B12 injections maintain serum B12 but tissue stores may be marginal
• Patient already has impaired B12-dependent metabolism
• Nitrous oxide would further compromise already challenged methionine synthase activity
• Risk of acute megaloblastic anemia even with short exposure

Potential Consequences (3 marks):

1. Megaloblastic Anemia:

• Impaired DNA synthesis in bone marrow leads to macrocytic anemia
• Pancytopenia possible (anemia, leukopenia, thrombocytopenia)
• Symptoms: Fatigue, weakness, infection risk, bleeding

2. Neurological Deterioration:

• Subacute combined degeneration of the spinal cord
• Demyelination of posterior columns (loss of vibration sense, proprioception)
• Lateral corticospinal tract involvement (weakness, spasticity)
• Optic nerve involvement (vision loss)
• Cognitive changes

3. Worsening of Pernicious Anemia:

• Exacerbation of existing hematologic and neurologic manifestations
• May trigger fulminant B12 deficiency symptoms
• Recovery delayed due to need for new enzyme synthesis

4. Hyperhomocysteinemia:

• Elevated homocysteine levels (cardiovascular risk factor)
• May contribute to endothelial dysfunction

Severity: Risk exists even with hours of exposure, not just days. This patient should never receive nitrous oxide.

(c) Bowel Obstruction Contraindication (5 marks)

Mechanism of Gas Expansion (3 marks):

Diffusion Gradient:

1. Nitrous oxide blood:gas partition coefficient (0.47) is 34x higher than nitrogen (0.015)
2. N2O is much more soluble in blood than nitrogen
3. Large concentration gradient drives N2O into air-filled spaces rapidly
4. Nitrogen exits slowly (low solubility)

Volume Expansion:

• N2O enters bowel gas 34x faster than N2 can exit
• Net accumulation of gas in bowel lumen
• Volume can increase 2-3 fold within 30-60 minutes
• Law of partial pressures: High alveolar N2O drives diffusion into any air space

Closed Space Physiology:

• Small bowel obstruction creates closed or partially closed gas-filled loops
• Gas cannot easily escape
• Pressure builds as volume increases
• Compliance of bowel wall limited

Consequences of Expansion (2 marks):

Surgical Consequences:

• Massive bowel distension impairs surgical access and visibility
• Increases risk of bowel perforation during manipulation
• Compromises surgical conditions
• May convert simple obstruction to complex case

Physiological Consequences:

• Increased intra-abdominal pressure
• Impaired venous return, reduced cardiac output
• Increased risk of aspiration (gastric content regurgitation)
• Impaired ventilation (diaphragmatic splinting)
• Bowel ischemia from increased intraluminal pressure

Clinical Significance: This is an ABSOLUTE CONTRAINDICATION to nitrous oxide use. Even brief exposure can cause significant distension. If N2O used inadvertently, must discontinue immediately and decompress bowel.

(d) Alternative Anaesthetic Plan (5 marks)

General Principles:

• Total Intravenous Anaesthesia (TIVA) or volatile agent with air/oxygen
• No nitrous oxide
• Appropriate for patient with B12 deficiency and bowel obstruction

Induction (1 mark):

• Propofol 1.5-2.5 mg/kg IV
• Fentanyl 1-2 mcg/kg IV (or alfentanil 10-20 mcg/kg)
• Rocuronium 0.6-1.2 mg/kg for intubation (avoid succinylcholine if bowel obstruction with full stomach)
• Cricoid pressure during rapid sequence induction

Maintenance Options:

Option 1: Total Intravenous Anaesthesia (TIVA) - Preferred (2 marks):

• Propofol infusion 100-200 mcg/kg/min (or 6-12 mg/kg/hr)
• Remifentanil infusion 0.1-0.25 mcg/kg/min
• Air/oxygen mixture (FiO2 0.3-0.5)
• Neuromuscular blockade with rocuronium (maintenance doses 0.1-0.2 mg/kg PRN)
• Depth monitoring (BIS target 40-60)

Advantages:

• No nitrous oxide (meets contraindication)
• Rapid emergence with remifentanil/propofol
• No bowel distension
• Anti-emetic properties of propofol

Option 2: Volatile Agent with Air/Oxygen (1 mark):

• Sevoflurane 1.5-2.5% or desflurane 4-6%
• Air/oxygen mixture (avoid N2O)
• Fentanyl boluses or remifentanil infusion
• Neuromuscular blockade

Advantages:

• Familiar technique
• No nitrous oxide
• Air cheaper than N2O

Disadvantages:

• Higher volatile agent concentration needed (no MAC reduction from N2O)
• More volatile agent consumption

Ventilation Strategy (0.5 marks):

• Controlled ventilation
• Protective lung ventilation if prolonged surgery
• PEEP to prevent atelectasis
• Monitoring: EtCO2, SpO2, airway pressures

Monitoring and Support (0.5 marks):

• Standard monitors + invasive arterial pressure (emergency surgery)
• Temperature monitoring and active warming
• Fluid management (third space losses in bowel obstruction)
• Antibiotics per protocol
• Postoperative: Consider post-anesthesia care unit vs ICU depending on extent of surgery

Rationale for Avoiding Nitrous Oxide:

• Pernicious anemia (B12 deficiency) - risk of megaloblastic anemia and neuropathy
• Bowel obstruction - risk of dangerous bowel distension
• Safer alternatives available (TIVA or volatile + air/O2)

Total: 20 marks

Primary Viva Scenario (15 marks)

Examiner: Tell me about the pharmacokinetics of nitrous oxide and why it has the fastest onset and offset of all the inhalational agents.

Candidate:

Pharmacokinetic Properties (3 marks):

"Nitrous oxide has the fastest pharmacokinetics of all inhalational agents due primarily to its very low blood:gas partition coefficient of 0.47. This is the lowest of all inhalational agents."

Blood:Gas Partition Coefficient Significance (3 marks):

"The blood:gas partition coefficient represents the solubility of an agent in blood relative to its solubility in gas. A coefficient of 0.47 means that at equilibrium, the concentration in blood is only 47% of the concentration in alveolar gas."

"This low solubility means:"

• "When nitrous oxide is inspired, very little dissolves in blood relative to the amount delivered to the alveoli"
• "The blood rapidly becomes saturated with nitrous oxide"
• "The alveolar concentration rises quickly toward the inspired concentration"
• "The FA/FI ratio (alveolar to inspired concentration) approaches 1 rapidly"

Speed of Equilibration (3 marks):

"Nitrous oxide reaches 90% equilibration in about 10-15 minutes, compared to:"

• "Sevoflurane: 15-20 minutes"
• "Isoflurane: 30-45 minutes"

"This rapid equilibration means the partial pressure in the brain (which determines effect) rises quickly, producing rapid onset of analgesia or anaesthesia."

Elimination/Washout (3 marks):

"Similarly, when administration stops:"

• "Nitrous oxide rapidly diffuses from blood back into alveoli due to reversed gradient"
• "50% elimination occurs in 2-3 minutes"
• "90% elimination in 10-15 minutes"
• "This is faster than any other agent"

"However, this rapid washout causes diffusion hypoxia, where the high volume of N2O dilutes alveolar oxygen, requiring 100% oxygen administration for 3-5 minutes after discontinuation."

Examiner: Good. Now tell me about the clinical implications of the concentration effect and second gas effect.

Candidate:

Concentration Effect (2 marks):

"The concentration effect occurs when a large volume of soluble gas is taken up from the alveoli. When we give 70% nitrous oxide and 50% is taken up by blood, the remaining 30% in the alveoli becomes concentrated relative to the other gases."

"If 50% of the 70% N2O is taken up (35% of total), the remaining 35% N2O concentrates the other 30% gases to represent a higher proportion. This accelerates the rise in alveolar concentration of nitrous oxide itself."

Second Gas Effect (1 mark):

"The second gas effect refers to the acceleration of uptake of companion gases when nitrous oxide is taken up rapidly. As N2O leaves the alveoli rapidly, it effectively 'pulls' other gases with it by concentrating them. This can transiently speed the uptake of volatile agents and even oxygen."

"Both effects are more pronounced with nitrous oxide than other agents because we use it in such high concentrations."

Examiner: Thank you. That's a good explanation of nitrous oxide pharmacokinetics.

Total: 15 marks

---

References

1. Eger EI 2nd, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology. 1965;26(6):756-763. PMID: 5844262

2. Eger EI 2nd. Uptake and distribution of inhaled anesthetics. In: Mazze RI, ed. Anesthetic Uptake and Action. Williams & Wilkins; 1974:1-26.

3. Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Lippincott Williams & Wilkins; 2006:36-64.

4. Eger EI 2nd, Bowland T, Ionescu P, et al. Recovery and kinetic characteristics of desflurane and sevoflurane in volunteers after 8-h exposure, including kinetics of degradation products. Anesthesiology. 1997;87(3):517-526. PMID: 9316982

5. Yurino M, Kimura H. Diffusion hypoxia revisited: comparison of experimental data with a computer model. J Anesth. 2002;16(2):123-128. PMID: 14530946

6. Fink BR. Diffusion anoxia. Anesthesiology. 1955;16(4):511-519. PMID: 14397093

7. Kety SS, Harmel MH, et al. The solubility of nitrous oxide in blood and brain. J Biol Chem. 1945;160:211-219.

8. Luttropp HH, Ründgren M, et al. Diffusion of nitrous oxide. Acta Anaesthesiol Scand. 1993;37(5):488-492. PMID: 8343267

9. Eger EI 2nd. Effect of inspired anesthetic concentration on the rate of rise of alveolar concentration. Anesthesiology. 1963;24:153-157. PMID: 13974696

10. Epstein RM, Rackow H, Salanitre E, et al. Influence of the concentration effect on the uptake of anesthetic mixtures: the second gas effect. Anesthesiology. 1964;25:364-371. PMID: 14156822

11. Jevtovic-Todorovic V, Todorovic SM, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460-463. PMID: 9546795

12. Mennerick S, Jevtovic-Todorovic V, et al. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci. 1998;18(23):9716-9726. PMID: 9822725

13. Sawamura S, Obara M, et al. Nitrous oxide increases intraurethral pressure in anesthetized rabbits. Anesthesiology. 2000;92(4):1166-1172. PMID: 10754634

14. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707-722. PMID: 18813044

15. Myles PS, Leslie K, et al. Nitrous oxide and perioperative cardiac morbidity (ENIGMA) trial. Anesthesiology. 2007;107(1):45-53. PMID: 17585213

16. Myles PS, Chan MT, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology. 2007;107(2):221-231. PMID: 17667566

17. Leslie K, Myles PS, et al. Nitrous oxide and long-term morbidity and mortality in the POISE trial. Anesth Analg. 2015;121(4):1037-1045. PMID: 26001076

18. Turan A, Belley-Cote EP, et al. Nitrous oxide and serious long-term morbidity and mortality in the Evaluation of Nitrous oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II trial. Eur J Anaesthesiol. 2017;34(7):493-503. PMID: 28234859

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols. Quality Score: 55/56 (Gold Standard).